We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Portable Rapid Diagnostic Assay Identifies Hemorrhaging Patients Using Small Blood Sample

By LabMedica International staff writers
Posted on 29 Aug 2023
Print article
Image: A prototype of the portable internal hemorrhage diagnostic tool for prehospital settings (Photo courtesy of DioTeX)
Image: A prototype of the portable internal hemorrhage diagnostic tool for prehospital settings (Photo courtesy of DioTeX)

Hemorrhaging occurs when blood vessels are damaged due to a traumatic event, leading to either visible external or hidden internal bleeding. While external bleeding is easily detectable, internal bleeding, also referred to as internal hemorrhaging, remains hidden from plain sight. Diagnosing internal bleeding demands clinical suspicion and subsequent assessment. Within hospital settings, advanced imaging can confirm these assessments, enabling timely surgical intervention to save lives. However, current methods for detecting hemorrhage are insufficient and require skilled operators, presenting significant diagnostic challenges. Now, a revolutionary internal hemorrhage diagnostic tool could change all that.

DioTeX Diagnostics (Baltimore, MD, USA), comprising a team of undergraduate biomedical engineers from Johns Hopkins University (Baltimore, MD, USA), is developing a portable, dependable, and accessible internal hemorrhage diagnostic tool. Their approach involves using a specific biomarker associated with hemorrhage to create a rapid immunochemistry-based test. By analyzing a small blood sample, this tool can swiftly identify patients with internal bleeding. This test has the potential to revolutionize internal hemorrhage diagnosis, as it can be conducted accurately and consistently by individuals with minimal training. This innovation holds the promise of faster and more appropriate hemorrhage care, potentially saving thousands of lives annually.

DioTeX has built a prototype of its portable rapid diagnostic assay designed to detect blood biomarkers linked to trauma-induced hemorrhage. This advancement aims to enhance the evaluation and management of internal trauma. Using the device, critical diagnostic results can be obtained and interpreted by anyone, regardless of location. To utilize the device, a blood sample is collected from behind the ear of a patient who may be experiencing internal bleeding. This process employs DioTeX's proprietary blood drawing mechanism. After approximately 5 minutes, users can interpret the test device's reading. A single line indicates no hemorrhage, while two lines indicate the presence of bleeding. The testing device requires minimal training, making it practical for use in settings with limited resources and in rural areas.

Related Links:
DioTeX Diagnostics 
Johns Hopkins University 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.